Article
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2005
Lepper Erin R, Baker Sharyn D, Permenter Matt, Ries Nicole, van Schaik Ron H N, Schenk Paul W, Price Douglas K, Ahn Danielle, Smith Nicola F, Cusatis George, Ingersoll Roxann G, Bates Susan E, Mathijssen Ron H J, Verweij Jaap, Figg William D, Sparreboom Alex
Abstract excerpt
PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe. EXPERIMENTAL DESIGN: Five variants in CYP3A4 and CYP3A5 were evaluated in 58 patients (21 women and 37 men) receiving a short i.v. bolus of midazolam (dose, 0.0145 or 0.025 mg/kg). Midazolam concentrations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
